| Title |
Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, April 2005
|
| DOI | 10.1007/s00280-005-1033-0 |
| Pubmed ID | |
| Authors |
Ronald de Wit, Matti Aapro, Peter R Blower |
| Abstract |
5-HT3-receptor antagonists are the current antiemetic 'gold standard' for chemotherapy- and radiotherapy-induced nausea and vomiting. Interestingly, studies have shown that patients experiencing poor control of acute chemotherapy-induced nausea and vomiting with one antiemetic therapy may respond well to another agent, including a drug of the same class. This review examines pharmacological differences between the 5-HT3-receptor antagonists in order to determine potential reasons for their differing efficacy, particularly in relation to refractory emesis. Differences in drug metabolism by the cytochrome P450 system, inadequate dosing of the respective agents, differences in onset and duration of action, and effects on serotonin release and reuptake are discussed. |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Indonesia | 1 | 3% |
| Japan | 1 | 3% |
| United States | 1 | 3% |
| Germany | 1 | 3% |
| Unknown | 30 | 88% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 18% |
| Student > Master | 4 | 12% |
| Researcher | 4 | 12% |
| Student > Ph. D. Student | 4 | 12% |
| Professor | 3 | 9% |
| Other | 3 | 9% |
| Unknown | 10 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 29% |
| Biochemistry, Genetics and Molecular Biology | 4 | 12% |
| Agricultural and Biological Sciences | 4 | 12% |
| Nursing and Health Professions | 2 | 6% |
| Chemistry | 2 | 6% |
| Other | 1 | 3% |
| Unknown | 11 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 April 2023.
All research outputs
#7,856,604
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#688
of 2,501 outputs
Outputs of similar age
#20,901
of 59,060 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#9
of 22 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 59,060 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.